PharmaceuticalField the gateaway to a commercial career is pharma

News

image description

GPs 'are voting with their feet' as they struggle to meet current demands

Read more

Deutsche Bank issues report about the advantages of 'PfizerKline'

Read more

The healthcare giant plans to file at least 10 new molecular entities by 2019, each with the potential to exceed $1 billion in revenue.

Read more

Deal could be worth $A750 million ($600 million) for the NASH treatment

Read more

Biotech medicines now make up around half of the company’s pipeline

Read more

Stock-and-cash deal will create a major player in US generics market

Read more

The Academy of Medical Royal Colleges is bringing a US initiative to get doctors to stop using interventions with no benefit to the UK

Read more

The compound shrank tumours in people with advanced ALK-positive non-small cell lung cancer whose disease had progressed following treatment with Pfizer’s Xalkori.

Read more

The Scottish Medicines Consortium has given the green light to seven new medicines for use on the NHS

Read more

The firm, best-known for the hugely expensive ultra-rare blood disease treatment Soliris (eculizumab), is building its first ever biologics manufacturing plant outside the USA

Read more

GlaxoSmithKline has teamed up with the University of North Carolina at Chapel Hill in a 'unique public-private partnership'

Read more

Have Your Say

No running polls,
please check back
soon.

Pf Archive

Increase your knowledge. Browse the Pf Archive.





Search

Upload
Your CV

Register

Quick Job Search

Looking to make a move? Find your next job here.

Go

RSS
Updates

Subscribe

Career Centre

Need career advice? Visit
our Career
Centre.

Go